Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

This agreement solidifies Pfizer at the forefront of innovative cancer research and further enhances the company’s robust oncology pipeline ... the SSGJ-707 program including novel combination ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer Inc. continues to showcase potential practice-changing research and next-generation candidates across its robust Oncology portfolio at the European Society for Medical Oncology Congress ...

Wall Street analysts predict Pfizer’s average 12-month price target at $32.77, with a high of $45.00 and a low of $27.00. This represents an 11.39% increase from the current price of $29.42.

Pfizer Inc PFE, one of the world’s largest pharmaceutical firms, is on the verge of a bullish Golden Cross, a significant technical indicator suggesting potential upward momentum for the stock.